Pre-operative Therapy in Breast Cancer

NCT05621564 · tracked via the Priya Life Science China tracker

Sponsor

RenJi Hospital

Phase

Observational

Started

2022-11-01

Last updated

2026-08-04

Condition(s) studied

Breast Cancer

Investigational drug(s) / intervention(s)

pre-operative therapy

pre-operative therapy: pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy

Study summary

This is a prospective and retrospective study to evaluate the effect of pre-operative therapy on response and survival, and compare the difference in response and survival by pre-operative regimen or by patient's clinicopathological characteristic in early or advanced breast cancer.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Female, Aged ≥18 years * Histologically confirmed primary breast cancer * Plan to receive pre-operative therapy * Adequate organ function Exclusion Criteria: * History of neurological or psychological disease, including epilepsy or dementia * Not suitable to participate in this study judged by investigators

Primary outcome measure(s)

Pathologic Complete Response — at surgery
ypT0 ypN0, ypT0/is ypN0

Trial sites (1)

Facility	City	Region	Status
Renji Hospital, School of Medicine, Shanghai Jiaotong University	Shanghai	China	Recruiting

More RenJi Hospital trials in China

The Efficacy of Gallium[68Ga]NOTA-DNA Multivalent SGC8 Injection for Bladder Tumour Imaging Recruiting

Renal Biopsies in Post-liver Transplantation Patients With Renal Impairment Recruiting

Ciprofol vs Propofol for Hemodynamic Stability in Patients Having General Anesthesia for Endovascular Thrombectomy After Ischemic Stroke Starting soon

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer Recruiting

JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases Starting soon

Other trials for the same condition

A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors Recruiting

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC Active, not recruiting

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer Recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) Recruiting

Myeloprotection With Trilaciclib in Pan-cancer Population Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05621564 on ClinicalTrials.gov ↗ ← All trials in China